Please use this identifier to cite or link to this item: https://doi.org/10.1038/jcbfm.2008.98
DC FieldValue
dc.titleThe role of animal models in evaluating reasonable safety and efficacy for human trials of cell-based interventions for neurologic conditions
dc.contributor.authorRegenberg, A.
dc.contributor.authorMathews, D.J.H.
dc.contributor.authorBlass, D.M.
dc.contributor.authorBok, H.
dc.contributor.authorCoyle, J.T.
dc.contributor.authorDuggan, P.
dc.contributor.authorFaden, R.
dc.contributor.authorFinkel, J.
dc.contributor.authorGearhart, J.D.
dc.contributor.authorHillis, A.
dc.contributor.authorHoke, A.
dc.contributor.authorJohnson, R.
dc.contributor.authorJohnston, M.
dc.contributor.authorKahn, J.
dc.contributor.authorKerr, D.
dc.contributor.authorKing, P.
dc.contributor.authorKurtzberg, J.
dc.contributor.authorLiao, S.M.
dc.contributor.authorMcDonald, J.W.
dc.contributor.authorMcKhann, G.
dc.contributor.authorNelson, K.B.
dc.contributor.authorRao, M.
dc.contributor.authorSiegel, A.W.
dc.contributor.authorSmith, K.
dc.contributor.authorSolter, D.
dc.contributor.authorSong, H.
dc.contributor.authorSugarman, J.
dc.contributor.authorVescovi, A.
dc.contributor.authorYoung, W.
dc.contributor.authorGreely, H.T.
dc.contributor.authorTraystman, R.J.
dc.date.accessioned2016-11-11T08:01:29Z
dc.date.available2016-11-11T08:01:29Z
dc.date.issued2009-01
dc.identifier.citationRegenberg, A., Mathews, D.J.H., Blass, D.M., Bok, H., Coyle, J.T., Duggan, P., Faden, R., Finkel, J., Gearhart, J.D., Hillis, A., Hoke, A., Johnson, R., Johnston, M., Kahn, J., Kerr, D., King, P., Kurtzberg, J., Liao, S.M., McDonald, J.W., McKhann, G., Nelson, K.B., Rao, M., Siegel, A.W., Smith, K., Solter, D., Song, H., Sugarman, J., Vescovi, A., Young, W., Greely, H.T., Traystman, R.J. (2009-01). The role of animal models in evaluating reasonable safety and efficacy for human trials of cell-based interventions for neurologic conditions. Journal of Cerebral Blood Flow and Metabolism 29 (1) : 1-9. ScholarBank@NUS Repository. https://doi.org/10.1038/jcbfm.2008.98
dc.identifier.issn0271678X
dc.identifier.urihttp://scholarbank.nus.edu.sg/handle/10635/130152
dc.description.abstractProgress in regenerative medicine seems likely to produce new treatments for neurologic conditions that use human cells as therapeutic agents; at least one trial for such an intervention is already under way. The development of cell-based interventions for neurologic conditions (CBI-NCs) will likely include preclinical studies using animals as models for humans with conditions of interest. This paper explores predictive validity challenges and the proper role for animal models in developing CBI-NCs. In spite of limitations, animal models are and will remain an essential tool for gathering data in advance of first-in-human clinical trials. The goal of this paper is to provide a realistic lens for viewing the role of animal models in the context of CBI-NCs and to provide recommendations for moving forward through this challenging terrain. © 2009 ISCBFM All rights reserved.
dc.description.urihttp://libproxy1.nus.edu.sg/login?url=http://dx.doi.org/10.1038/jcbfm.2008.98
dc.sourceScopus
dc.subjectClinical trials
dc.subjectModeling
dc.subjectNeurologic conditions
dc.subjectStem and progenitor cells
dc.typeReview
dc.contributor.departmentDUKE-NUS GRADUATE MEDICAL SCHOOL S'PORE
dc.description.doi10.1038/jcbfm.2008.98
dc.description.sourcetitleJournal of Cerebral Blood Flow and Metabolism
dc.description.volume29
dc.description.issue1
dc.description.page1-9
dc.description.codenJCBMD
dc.identifier.isiut000262110200001
Appears in Collections:Staff Publications

Show simple item record
Files in This Item:
There are no files associated with this item.

Google ScholarTM

Check

Altmetric


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.